About PNAV Digital

This author has not yet filled in any details.
So far PNAV Digital has created 2 blog entries.

Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress

SOUTH SAN FRANCISCO, CA, June 26, 2026 – Star Therapeutics, a late clinical-stage biotechnology company focused on the discovery and development of life-changing therapies for diseases with significant unmet need, today announced an upcoming oral presentation of complete safety and efficacy data...

By |2026-06-25T14:02:34-05:00June 25, 2026|Press Release|0 Comments
Read More

Star Therapeutics Receives FDA Rare Pediatric Disease and Breakthrough Therapy Designations for VGA039 in Von Willebrand Disease Prophylaxis

SOUTH SAN FRANCISCO, CA, April 21, 2026 – Star Therapeutics, a late clinical-stage biotechnology company focused on the discovery and development of life-changing therapies for diseases with significant unmet need, today announced that the U.S. Food and Drug Administration (FDA)...

By |2026-04-20T17:27:44-05:00April 21, 2026|Press Release|0 Comments
Read More

THANK YOU

We look forward to connecting with you